Investigations into the molecular mechanisms of cholestasis have revealed intricate and intriguing details of bile salt metabolism as well as its regulatory mechanisms in health and disease. Extensive studies on genotype-phenotype correlations in monogenic diseases, such as progressive familial and benign recurrent intrahepatic cholestasis, facilitate diagnostics and improve the risk assessment of hepatobiliary transporter gene variants in bile transport pathophysiology. While the comparatively easy targets in monogenic cholestasis have been identified for some time now, progress in complex liver disease is rather laborious but steady. Genome-wide association scans are the next step in gathering information about common contributors towards polygenic (multifactorial) cholestatic diseases. New determinants of bile salt metabolism affecting feedback loops within the liver or the enterohepatic circulation are presently under investigation for their contribution towards complex cholestatic syndromes.

Keywords:
ABC transporters, Genome-wide scan, Personalized medicine, Polygenic disease
1.
Getting personal. Nature 2008;455:1007.
2.
European Society of Human Genetics: Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2010;18:1271–1273.
3.
Positively disruptive. Nat Genet 2008;40:119.
4.
Krawczyk M, Müllenbach R, Weber SN, et al: Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010;7:669–681.
5.
Oda T, Elkahloun AG, Pike BL, et al: Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16:235–242.
6.
Kamath BM, Krantz ID, Spinner NB, et al: Monozygotic twins with a severe form of Alagille syndrome and phenotypic discordance. Am J Med Genet 2002;112:194–197.
7.
Gissen P, Tee L, Johnson CA, et al: Clinical and molecular genetic features of ARC syndrome. Hum Genet 2006;120:396–409.
8.
Cullinane AR, Straatman-Iwanowska A, Zaucker A, et al: Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet 2010;42:303–312.
9.
Deleuze JF, Jacquemin E, Dubuisson C, et al: Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996;23:904–908.
10.
Bull LN, van Eijk MJ, Pawlikowska L, et al: A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998;18:219–224.
11.
Strautnieks SS, Bull LN, Knisely AS, et al: A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233–238.
12.
Jacquemin E, De Vree JM, Cresteil D, et al: The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448–1458.
13.
Strautnieks SS, Byrne JA, Pawlikowska L, et al: Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 2008;134:1203–1214.
14.
Paulusma CC, Groen A, Kunne C, et al: Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006;44:195–204.
15.
Verhulst PM, van der Velden LM, Oorschot V, et al: A flippase-independent function of ATP8B1, the protein affected in familial intrahepatic cholestasis type 1, is required for apical protein expression and microvillus formation in polarized epithelial cells. Hepatology 2010;51:2049–2060.
16.
Ray NB, Durairaj L, Chen BB, et al: Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia. Nat Med 2010;16:1120–1127.
17.
Smit JJ, Schinkel AH, Oude Elferink RP, et al: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451–462.
18.
Pawlikowska L, Strautnieks S, Jankowska I, et al: Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol 2010;53:170–178.
19.
Davit-Spraul A, Fabre M, Branchereau S, et al: ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010;51:1645–1655.
20.
Dixon PH, Weerasekera N, Linton KJ, et al: Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000;9:1209–1217.
21.
Müllenbach R, Linton KJ, Wiltshire S, et al: ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 2003;40:e70.
22.
Savander M, Ropponen A, Avela K, et al: Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 2003;52:1025–1029.
23.
Wasmuth HE, Glantz A, Keppeler H, et al: Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007;56:265–270.
24.
Knisely AS, Strautnieks SS, Meier Y, et al: Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006;44:478–486.
25.
Byrne JA, Strautnieks SS, Ihrke G, et al: Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing. Hepatology 2009;49:553–567.
26.
Ho RH, Leake BF, Kilkenny DM, et al: Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 2010;20:45–57.
27.
Müllenbach R, Lammert F: The transporter ‘variome’: the missing link between gene variants and bile salt transporter function. Hepatology 2009;49:352–354.
28.
Hayashi H, Sugiyama Y: 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 2007;45:1506–1516.
29.
Van der Velden LM, Stapelbroek JM, Krieger E, et al: Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 2010;51:286–296.
30.
Meier Y, Pauli-Magnus C, Zanger UM, et al: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006;44:62–74.
31.
Lang C, Meier Y, Stieger B, et al: Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007;17:47–60.
32.
Meier Y, Zodan T, Lang C, et al: Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008;14:38–45.
33.
Dixon PH, van Mil SW, Chambers J, et al: Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009;58:537–544.
34.
Hirschfield GM, Liu X, Xu C, et al: Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544–2555.
35.
Daly AK, Donaldson PT, Bhatnagar P, et al: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816–819.
36.
Liu X, Invernizzi P, Lu Y, et al: Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010;42:658–660.
37.
Zimmer V, Müllenbach R, Simon E, et al: Combined functional variants of hepatobiliary transporters and FXR aggravate intrahepatic cholestasis of pregnancy. Liver Int 2009;29:1286–1288.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.